Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
Emerging evidence supports a key role for the gut microbiota in metabolic diseases, including type 2 diabetes (T2D) and obesity. The dipeptidyl peptidase-4 inhibitor vildagliptin is highly efficacious in treating T2D. However, whether vildagliptin can alter the gut microbiome is still unclear. This study aimed to identify whether vildagliptin modifies the gut microbiota structure during T2D treatment. Diabetic Sprague-Dawley (SD) rats were induced by a high-fat diet and streptozotocin injection (HFD/STZ). Diabetic rats were orally administered a low dose of vildagliptin (LV, 0.01 g/kg/d vildagliptin), high dose of vildagliptin (HV, 0.02 g/kg/d vildagliptin), or normal saline for 12 weeks. Fasting blood glucose, blood glucose after glucose loading, and serum insulin levels were significantly reduced in the LV and HV groups compared with those in the T2D group. The serum GLP-1 level increased more in the vildagliptin-treated group than in the T2D group. Pyrosequencing of the V3-V4 regions of 16S rRNA genes revealed that vildagliptin significantly altered the gut microbiota. The operational taxonomic units (OTUs) and community richness (Chao1) index were significantly reduced in the vildagliptin and diabetic groups compared with those in the control group. At the phylum level, a higher relative abundance of Bacteroidetes, lower abundance of Firmicutes, and reduced ratio of Fimicutes/Bacteroidetes were observed in the vildagliptin-treated group. Moreover, vildagliptin treatment increased butyrate-producing bacteria, including Baceroides and Erysipelotrichaeae, in the diabetic rats. Moreover, Lachnospira abundance was significantly negatively correlated with fasting blood glucose levels. In conclusion, vildagliptin treatment could benefit the communities of the gut microbiota.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nonetheless, vildagliptin reduces Firmicutes to Bacteroidetes ratio, increases Lactobacilli spp. and increases propionate production [308].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [308]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
Naïve Bayesian Classifier for Rapid Assignment of rRNA Sequences into the New Bacterial Taxonomy
Wang, Q., Garrity, G. M., Tiedje, J. M., & Cole, J. R. (2007) · Applied and Environmental Microbiology · doi:10.1128/aem.00062-07 · Cited by 19,885
UPARSE: highly accurate OTU sequences from microbial amplicon reads
Edgar, R. C. (2013) · Nature Methods · doi:10.1038/nmeth.2604 · Cited by 16,707
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB
DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., Huber, T., Dalevi, D., Hu, P., & Andersen, G. L. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.03006-05 · Cited by 10,891
Diet rapidly and reproducibly alters the human gut microbiome
David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., Ling, A. V., Devlin, A. S., Varma, Y., Fischbach, M. A., et al. (2014) · Nature · doi:10.1038/nature12820 · Cited by 10,100
UniFrac: a New Phylogenetic Method for Comparing Microbial Communities
Lozupone, C., & Knight, R. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.12.8228-8235.2005 · Cited by 8,227
Obesity alters gut microbial ecology
Ley, R. E., Bäckhed, F., Turnbaugh, P., Lozupone, C. A., Knight, R. D., & Gordon, J. I. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504978102 · Cited by 6,176
Cani, P. D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A. M., Delzenne, N. M., & Burcelin, R. (2008) · Diabetes · doi:10.2337/db07-1403 · Cited by 4,819
Cited by
Benítez-Páez, A., Gómez del Pugar, E. M., López-Almela, I., Moya-Pérez, Á., Codoñer-Franch, P., & Sanz, Y. (2020) · mSystems · doi:10.1128/msystems.00857-19 · Cited by 337
“that could account for the beneficial roles of these bacteria in glucose metabolism and obesity-associated inflammation (29, 30).”
BackgroundDrug-microbiota interactions: an emerging priority for precision medicine
Zhao, Q., Chen, Y., Huang, W., Zhou, H., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01619-w · Cited by 268
“388 Moreover, vildagliptin has been reported to produce bene fi ts by modulating gut microbiota, leading to increased Lactobacilli and decreased Oscillibacter .”
BackgroundWang, Y., Dilidaxi, D., Wu, Y., Sailike, J., Sun, X., & Nabi, X.-H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109914 · Cited by 270
Li, H., Fang, Q., Nie, Q., Hu, J., Yang, C., Huang, T., Li, H., & Nie, S. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c01968 · Cited by 163
Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases
Zeng, Y., Wu, Y., Zhang, Q., & Xiao, X. (2024) · mBio · doi:10.1128/mbio.02032-23 · Cited by 150
“Similarly, DPP-4 inhibitor (PKF-275-055 or vildagliptin) treatment was reported to significantly decrease Firmicutes/Bacteroidetes ratios and increase butyrate-producing bacteria in diabetic and obese mice, similar to metformin (143, 144).”
BackgroundSelf-citationConsidering gut microbiota in treatment of type 2 diabetes mellitus
Adeshirlarijaney, A., & Gewirtz, A. T. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1717719 · Cited by 176
“These drugs reduced the diversity of microbiota, increased the abundances of SCFA-producing bacteria including Blautia, Roseburia, Clostridium, Baceroides, and Erysipelotrichaeae in gut microbiota and corrected the Bacteroidetes/Firmicutes ratio.(58,59) Therefore, it has been suggested that these drugs may have benefi…”
BackgroundBerberine alleviates insulin resistance by reducing peripheral branched-chain amino acids
Yue, S.-J., Liu, J., Wang, A.-T., Meng, X.-T., Yang, Z.-R., Peng, C., Guan, H.-S., Wang, C.-Y., & Yan, D. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00256.2018 · Cited by 130
“Most notably, distinctive traits of the gut microbiota, with a decrease of genera known as BCAA producers such as Prevotella, within the family Prevotellaceae, were observed in BBR-treated mice, which was similar with the oral antidiabetic agent, vildagliptin (48).”
ResultWu, I., Lin, C., Chang, L., Lee, C., Chiu, C., Hsu, H.-J., Sun, C., Chen, Y.-C., Kuo, Y., Yang, C.-W., et al. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.37421 · Cited by 139
“Of note, another significantly and inversely correlated genus, Lachnospiraceae ND3007 group, was associated with a decrease in blood glucose levels in diabetic rats [45].”
BackgroundThe role of the gut microbiota in health and cardiovascular diseases
Wang, L., Wang, S., Zhang, Q., He, C., Fu, C., & Wei, Q. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00091-2 · Cited by 122
Self-citationDing, Q., Cao, F., Lai, S., Zhuge, H., Chang, K., Valencak, T. G., Liu, J., Li, S., & Ren, D. (2022) · Food Research International · doi:10.1016/j.foodres.2022.111259 · Cited by 106
Olivares, M., Neyrinck, A. M., Pötgens, S. A., Beaumont, M., Salazar, N., Cani, P. D., Bindels, L. B., & Delzenne, N. M. (2018) · Diabetologia · doi:10.1007/s00125-018-4647-6 · Cited by 105
Zhou, L., Xiao, X., Zhang, Q., Zheng, J., Li, M., Yu, M., Wang, X., Deng, M., Zhai, X., & Li, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00516 · Cited by 105
“Gut Microbiota Analysis The gut microbiota was analyzed according to the methods described in our previous publication (24).”
MethodSelf-citationThe Effect of Short-Term Consumption of Lactic Acid Bacteria on the Gut Microbiota in Obese People
Burakova, I. Y., Dmitrievna, S. Y., Vladimirovna, G. M., Syromyatnikov, M., Chizhkov, P. A., Попов, Е. С., & Popov, V. N. (2022) · Nutrients · doi:10.3390/nu14163384 · Cited by 101
“the Lachnospiraceae ND3007 group has been associated with a decrease in the blood glucose levels in rats with diabetes [33].”
BackgroundThe Relationships between Gut Microbiota and Diabetes Mellitus, and Treatments for Diabetes Mellitus
Crăciun, C.-I., Neag, M. A., Cătinean, A., Mitre, A. O., Rusu, A., Bala, C. G., Román, G., Buzoianu, A. D., Muntean, D. M., & Craciun, A. E. (2022) · Biomedicines · doi:10.3390/biomedicines10020308 · Cited by 105
Zhang, M., Feng, R., Yang, M., Cheng, Q., Wang, Z., Liu, W., & Ma, J. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000717 · Cited by 94
Zhang, Y., Peng, Y., Zhao, L., Zhou, G., & Li, X. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114033 · Cited by 94
Crosstalk between gut microbiota and antidiabetic drug action
Kyriachenko, Y., Falalyeyeva, T. M., Korotkyi, O., Molochek, N., & Kobyliak, N. M. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i3.154 · Cited by 85
Improvement of Colonic Immune Function with Soy Isoflavones in High-Fat Diet-Induced Obese Rats
Luo, Q., Cheng, D., Huang, C., Li, Y., Lao, C., Xia, Y., Liu, W., Gong, X., Hu, D., Ли, Б., et al. (2019) · Molecules · doi:10.3390/molecules24061139 · Cited by 84
“Lachnospira, an acetate-producing bacteria [54,59], is associated with an increased level of blood glucose [60].”
BackgroundJuárez‐Fernández, M., Román-Sagüillo, S., Porras, D., García‐Mediavilla, M. V., Linares, P., Ballesteros-Pomar, M. D., Urioste-Fondo, A., Álvarez-Cuenllas, B., González‐Gallego, J., Sánchez‐Campos, S., et al. (2021) · Nutrients · doi:10.3390/nu13082519 · Cited by 78
“Finally, Lachnospira decreased significantly in operated patients and was positively correlated with BMI, body fat and insulin levels, unlike a previous study in which Lachnospira was negatively correlated with BMI and fasting blood glucose [43].”
ResultYang, L., Lin, H., Lin, W., & Xu, X. (2020) · Biology · doi:10.3390/biology9080203 · Cited by 70
“SCFAs are the final products of fermentation by intestinal bacterial (mainly Bacteroides) and are also thought to be involved in the development of intestinal motility and intestinal diseases [47].”
BackgroundRoles of Gut Microbial Metabolites in Diabetic Kidney Disease
Fang, Q., Liu, N., Zheng, B., Guo, F., Zeng, X., Huang, X., & Ouyang, D. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.636175 · Cited by 75
Xue, M., Liu, Y., Xu, H., Zhou, Z., Ma, Y., Sun, T., Liu, M., Zhang, H., & Liang, H. W. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109393 · Cited by 70
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Hansen, N. W., & Sams, A. (2018) · Nutrients · doi:10.3390/nu10111590 · Cited by 65
“Interestingly, the DPP4 antagonist vildagliptin, used for the treatment of T2D, induces a higher relative abundance of Bacteroidetes, a lower abundance of Firmicutes, and thus a reduced ratio of Firm cutes/Bacteroidetes in r ts [96].”
BackgroundXu, H., Hiraishi, K., Kurahara, L. H., Nakano‐Narusawa, Y., Li, X., Hu, Y., Matsuda, Y., Zhang, H., & Hirano, K. (2021) · Nutrients · doi:10.3390/nu13041143 · Cited by 67
“Butyrate is a bacterial metabolite that could account for the beneficial roles of these bacteria in glucose metabolism and obesity-associated inflammation [28,29].”
Liu, W., Luo, Z., Zhou, J., & Sun, B. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.853771 · Cited by 78
Type 2 diabetes, gut microbiome, and systems biology: A novel perspective for a new era
Martínez-López, Y. E., Esquivel-Hernandez, D. A., Sánchez-Castañeda, J. P., Neri-Rosario, D., Guardado‐Mendoza, R., & Reséndis-Antonio, O. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2111952 · Cited by 65
“01 for each variable.(95) On the other hand, Lin-Wang et al.”
Argüello, H., Estellé, J., Leonard, F. C., Crispie, F., Cotter, P. D., O’Sullivan, Ó., Lynch, H., Walia, K., Duffy, G., Lawlor, P. G., et al. (2019) · mSystems · doi:10.1128/msystems.00021-19 · Cited by 68
Cao, T. T. B., Wu, K., Hsu, J., Chang, C., Chou, C., Lin, C.-Y., Liao, Y.-M., Lin, P.-C., Yang, L., & Lin, H. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.573891 · Cited by 54
“F_Verrucomicrobiaceae Verrucomicrobia 4 ↑ ↑ (2) ↑ (3) G_Akkermansia Verrucomicrobia 8 ↑ ↑ (6) ↑ ↑”
BackgroundInfluentialLi, Z., Jia, R., Luo, D., Lin, L., Zheng, Q., & Zhao, M. (2021) · Food & Function · doi:10.1039/d1fo01838h · Cited by 51
Oh, T. J., Sul, W. J., Oh, H. N., Lee, Y.-K., Lim, H. L., Choi, S. H., Park, K. S., & Jang, H. C. (2019) · Scientific Reports · doi:10.1038/s41598-019-56684-5 · Cited by 50
Liu, Y., & Lou, X. (2020) · Clinics · doi:10.6061/clinics/2020/e1277 · Cited by 51
Lim, J. J., Li, X., Lehmler, H., Wang, D., Gu, H., & Cui, J. Y. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa090 · Cited by 45
“There are several known adverse health effects of PCB exposure; epidemiological and animal models have demonstrated dysregulation in neurodevelopment (Klocke and Lein, 2020; Schug et al., 2015; Zhang et al., 2017), interference of thyroid hormone signaling (Li et al.”
BackgroundEffects of Oral Glucose-Lowering Agents on Gut Microbiota and Microbial Metabolites
Wang, D., Liu, J. Y., Zhou, L., Zhang, Q., Li, M., & Xiao, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.905171 · Cited by 52
Self-citationZhu, Y. G., Bai, J., Zhang, Y., Xiao, X., & Dong, Y. (2016) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2016.1197185 · Cited by 42
Self-citationThe emerging role of gut microbiota in cardiovascular diseases
Kumar, D., Mukherjee, S. S., Chakraborty, R., Roy, R. R., Pande, A., Patra, S., & Dey, S. (2021) · Indian Heart Journal · doi:10.1016/j.ihj.2021.04.008 · Cited by 43
Role of Gut Microbial Metabolites in Cardiovascular Diseases—Current Insights and the Road Ahead
Datta, S., Pasham, S., Sandeep, I. S., Boini, K. M., & Koka, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810208 · Cited by 46
Qin, S., He, Z., Wu, Y., Zeng, C., Zheng, Z., Zhang, H., Lv, C., Yuan, Y., Wu, H., Ye, J., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.819980 · Cited by 42
“The Lachnospiraceae_UCG010 was associated with an increase in blood glucose level (50), which was significantly decreased by HIDT compared to HFD.”
Li, G.-H., Huang, S., Li, X., Liu, X.-S., & Du, Q. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i46.7338 · Cited by 40
The pathogenic role of intestinal flora metabolites in diabetic nephropathy
Tian, E., Wang, F., Zhao, L., Sun, Y., & Yang, J. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1231621 · Cited by 36
“In another animal study it was confirmed that similar results were obtained with vildagliptin treatment (Zhang et al., 2017).”
ResultPapadopoulos, P., Tsigalou, C., Valsamaki, P. N., Konstantinidis, T. G., Voidarou, C. C., & Bezirtzoglou, E. (2022) · Biomedicines · doi:10.3390/biomedicines10050948 · Cited by 43
“The disease severity has been positively correlated with gut wall permeability [98], as the compromised blood flow to the lumen leads to the disruption of its integrity and the subsequent establishment of low-grade systemic inflammation [99].”
BackgroundLv, Y., Zhao, X. Y., Guo, W., Gao, Y., Yang, S., Li, Z., & Wang, G. (2018) · Journal of Diabetes Research · doi:10.1155/2018/1890978 · Cited by 38
“DPP-4 inhibitor Vildagliptin Bacteroidetes [68] Prevotellaceae [68] Ruminococcaceae [68] HFD/STZ SD rats [68]”
BackgroundBhushan, B., Singh, B. P., Saini, K., Kumari, M., Tomar, S. K., & Mishra, V. (2019) · Environmental Chemistry Letters · doi:10.1007/s10311-019-00914-9 · Cited by 29
Boeravinone B alleviates gut dysbiosis during myocardial infarction‐induced cardiotoxicity in rats
Chen, Y., Peng, L., Shi, S., Guo, G. F., & Wen, H. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16620 · Cited by 30
Zhao, J., Li, Y., Sun, M., Xin, L., Wang, T., Wei, L., Yu, C., Liu, M., Ni, Y., Lu, R., et al. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/6976394 · Cited by 31
Self-citationWu, X., Zhao, L., Zhāng, Y., Li, K., & Yang, J. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1166685 · Cited by 31
“And another DPP-4 inhibitor vildagliptin was found to increase SCFAproducing bacteria and alleviate insulin resistance in diabetic rats (Zhang et al., 2017).”
BackgroundDing, Q., Tian, J., Li, M., Lian, F., Zhao, L., Wei, X., Han, L., Zheng, Y., Gao, Z., Yang, H., et al. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.530160 · Cited by 31
“Vildagliptin also has a potential effect on inflammation due to the reduction of TLR and cytokine expression (Yan et al., 2016; Zhang et al., 2017).”
BackgroundSelf-citationPharmacomicrobiomics and type 2 diabetes mellitus: A novel perspective towards possible treatment
Jia, L., Huang, S., Sun, B., Shang, Y., & Zhu, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1149256 · Cited by 29
“Likewise, vildagliptin treatment also reduced the ratio of Fimicutes/ Bacteroidetes, and increased butyrate-producing bacteria, including Baceroides and Erysipelotrichaeae, in HFD-induced SD rats (96).”
BackgroundKaya, D., Kaji, K., Tsuji, Y., Yamashita, S., Kitagawa, K., Ozutsumi, T., Fujinaga, Y., Takaya, H., Kawaratani, H., Moriya, K., et al. (2019) · Cells · doi:10.3390/cells8101153 · Cited by 28
“A recent study on a rat diabetic model has found that vildagliptin treatment also provided a similar microbial modification following a high-fat diet/streptozotocin injection [32].”
BackgroundResultZhang, X., Ren, H., Zhao, C., Shi, Z., Li, Q., Yang, F., Zhou, X., Han, X., Wu, K., Zhong, H., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05768-5 · Cited by 30
Wang, Y., Yang, R., Hao, J. J., Sun, M., Wang, H., & Ren, H. (2021) · Journal of environmental chemical engineering · doi:10.1016/j.jece.2021.106533 · Cited by 22
Gut microbiome: New perspectives for type 2 diabetes prevention and treatment
Li, S.-X., & Guo, Y. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i31.7508 · Cited by 23
Du, C., Zuo, F., Cao, Y., & Zang, Y. (2023) · Food & Function · doi:10.1039/d3fo04118b · Cited by 25
Effect of metformin and metformin/linagliptin on gut microbiota in patients with prediabetes
Martínez-López, Y. E., Neri-Rosario, D., Esquivel-Hernandez, D. A., Padrón-Manrique, C., Vázquez-Jiménez, A., Sánchez-Castañeda, J. P., Giron-Villalobos, D., Mendoza-Ortíz, C., Reyes‐Escogido, M. D. L., Evia-Viscarra, M. L., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-60081-y · Cited by 23
“Weight loss was the primary predictor of improved IS, while weight regain T2D 48 .”
BackgroundInfluentialChen, Y., Xie, C., Lei, Y., Ye, D., Wang, L., Xiong, F., Wu, H., He, Q., Zhou, H., Li, L., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116582 · Cited by 25
Analysis of jejunum microbiota of HFD/STZ diabetic rats
Almugadam, B. S., Yang, P., & Tang, L. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111094 · Cited by 18
Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies
Trapanese, V., Dagostino, A., Natale, M. R., Giofrè, F., Vatalaro, C., Melina, M., Cosentino, F., Sergi, S., Imoletti, F., Spagnuolo, R., et al. (2025) · Life · doi:10.3390/life15060843 · Cited by 25
“In a similar vein, other studies have shown that the use of vildagliptin led to an increase in Bacteroidetes and a decrease in Firmicutes, a decrease in the Firmicutes/Bacteroidetes ratio, and an increase in butyrate-producing bacteria in obese and diabetic mice (Figure 4) [63,64].”
Song, Y., Huang, H., Jia, K., Zou, S., Yang, Y. J., & Yi, M. (2025) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2025.137296 · Cited by 18
Dietary ε-Polylysine Affects on Gut Microbiota and Plasma Metabolites Profiling in Mice
Zhang, X., Xu, B., Hou, Z., Xie, C., Niu, Y., Dai, Q., Yan, X., & Wu, D. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.842686 · Cited by 20
“In the adult period of mice, the genera Allobaculum, Lachnospiraceae UCG010 (57), Parasutterella (63), Ruminococcaceae, Odoribacter, Blautia, Holdemania (64), and Intestinimonas were induced by ε-polylysine, which positively correlated with lipid metabolism.”
BackgroundWang, T., Guan, K., Su, Q., Wang, X., Yan, Z., Kuang, K., Wang, Y., Zhang, Q., Zhou, X., & Liu, B. (2022) · Animals · doi:10.3390/ani12121504 · Cited by 18
“Family-XIIIAD3011-group, as a conditionally pathogenic bacterium, causes excessive insulin secretion in gut microbiota dysregulation or other pathogenic bacteria’s excitation states, thus resulting in hypoglycemic symptoms [60] that may be related to depression and metabolic disturbance.”
BackgroundSelf-citationSu, S., Wang, L., Fu, S., Zhao, J., He, X., Chen, Q., Belobrajdic, D. P., Yu, C., Liu, H., Wu, H., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1032622 · Cited by 19
“In related studies of diabetes, Lachnospiraceae UCG-010 was found to be closely related to elevated blood glucose level (p < 0.01; Zhang et al., 2017; Yang et al., 2021).”
BackgroundInfluentialLim, S. K., Sohn, M., Florez, J. C., Nauck, M. A., & Ahn, J. (2023) · Nutrients · doi:10.3390/nu15010248 · Cited by 20
“05), to conservatively detect a 25% difference in the Firmicutes/Bacteroidetes ratio between the two groups, which was based on previous studies showing increased Bacteroidetes and decreased Firmicutes in subjects with type 2 diabetes after DPP-4 inhibitor treatment [18,19].”
ResultMa, G., Yan, H., Tye, K. D., Tang, X., Luo, H., Li, Z., & Xiao, X. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.00413-24 · Cited by 20
“Blautia is a major producer of butyrate, a short-chain fatty acid, and experiments have shown that butyrate can have beneficial effects, such as maintaining glucose homeostasis and anti-obesity-related inflammatory characteristics (74, 77, 78).”
BackgroundSelf-citationPreclinical and clinical combination therapies in the treatment of anaplastic thyroid cancer
Gentile, D., Orlandi, P., Banchi, M., & Bocci, G. (2020) · Medical Oncology · doi:10.1007/s12032-020-1345-2 · Cited by 16
Downregulation of IL-18 Expression in the Gut by Metformin-induced Gut Microbiota Modulation
Lee, H., Kim, J., An, J., Lee, S., Choi, D., Kong, H., Song, Y., Park, I.-H., Lee, C., & Kim, K. (2019) · Immune Network · doi:10.4110/in.2019.19.e28 · Cited by 16
“Recently, the dipeptidyl peptidase-4 inhibitor vildagliptin has been shown to decrease the abundance of butyrate-producing bacteria including Bacteroides in the intestines of diabetic rats (19).”
BackgroundDike, K. S., Okafor, C. P., Ohabughiro, B. N., Maduwuba, M. C., Ezeokoli, O. T., Ayeni, K. I., Okafor, C. M., & Ezekiel, C. N. (2021) · Letters in Applied Microbiology · doi:10.1111/lam.13621 · Cited by 13
“Blautia and Stenotrophomonas are b predominantly beneficial bacteria residing in the gut and soil/rhizosphere, respectively (Ryan et al. 2009; Zhang et al. 2017; Ben ıtezP aez et al. 2020).”
BackgroundChronic corticosterone exposure disrupts hepatic and intestinal bile acid metabolism in chicken
Wu, L., Liu, X., Zhang, A., Chen, H., Zhao, R., & Jia, Y. (2023) · Frontiers in Veterinary Science · doi:10.3389/fvets.2023.1147024 · Cited by 13
“Differently, the abundance of Blautia decreased significantly in NASH patients (29, 30).”
BackgroundRui, L., & Chen, R. (2024) · Renal Failure · doi:10.1080/0886022x.2024.2385065 · Cited by 12
“This, in turn, triggers a cascade of noxious responses that can potentiate renal injury 8-12 .”
BackgroundKumar, S., Raj, V. S., Ahmad, A., & Saini, V. (2022) · Gut Pathogens · doi:10.1186/s13099-022-00513-0 · Cited by 11
“Zonula occludens-1 (ZO-1) that prevent leakage of solutes from gut [22, 23].”
BackgroundLoo, Y. T., Howell, K. S., Suleria, H. A. R., Zhang, P., Liu, S., & Ng, K. (2023) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2023.2187329 · Cited by 14
“Some Blautia species are recognised as butyrate-producing bacteria in the gut microbiota, where butyrate is a bacterial metabolite that associated with beneficial effects on glucose metabolism and obesity-associated inflammation (Udayappan et al. 2016; Zhang Q et al. 2017).”
Microbial Endocrinology: Host metabolism and appetite hormones interaction with gut microbiome
Ashraf, A., & Hassan, M. I. (2024) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2024.112281 · Cited by 13
Exploring the impact of type 2 diabetes and glucose-lowering drugs on gut microbiome dynamics
Tariq, H. M. A., Khan, N. Y., Manzoor, H., & Kayani, M. U. R. (2025) · Discover Medicine · doi:10.1007/s44337-025-00241-9 · Cited by 12
“To make optimal use of the gut microbiome as a target for T2D prevention and treatment, it will be important to address these issues, paving the way for more personalized and effective therapeutic approaches.”
Lagunas‐Rangel, F. A., Liao, S., Williams, M. J., Trukhan, V., Fredriksson, R., & Schiöth, H. B. (2023) · Biomedicines · doi:10.3390/biomedicines11113032 · Cited by 11
“In mice, modulation of the microbiome by DPP-4 inhibitors such as vildagliptin, sitagliptin, and saxagliptin has been reported to contribute to their hypoglycemic effects, mainly through an increase in butyrate-producing bacteria [47–49].”
BackgroundZhang, Y., Chen, C., Zhao, J., Stanton, C., Ross, R. P., Chen, W., & Yang, B. K. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.106229 · Cited by 9
Paripati, N., Nesi, L., Sterrett, J. D., Dawud, L. M., Kessler, L. R., Lowry, C. A., Perez, L. J., DeSipio, J., & Phadtare, S. (2023) · Microorganisms · doi:10.3390/microorganisms11102503 · Cited by 10
“Members of the Lachnospiraceae ND3007 group are short-chain fa tt y acid (SCFA) producers and have been linked to decreases in the blood glucose levels in rats with diabetes [49,50].”
BackgroundBhushan, B., Singh, B. P., Kumari, M., Mishra, V., Saini, K., & Singh, D. (2019) · Environmental chemistry for a sustainable world · doi:10.1007/978-3-030-04675-0_7 · Cited by 9
de Macedo, J. C. C., Guadagnini, D., Assalin, H. B., Oliveira, E. S., Magro, D. O., Alborghetti, M. R., Sforça, M. L., Rocco, S. A., Santos, A., & Saad, M. J. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-12990-9 · Cited by 8
Chen, Y., Shan, Y., Wang, T., Liu, Z., Zhao, Z., & He, Y. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s537001 · Cited by 11
“…humans, including metformin, 9,10 alpha-glucosidase inhibitors (AGIs) acarbose, 11 the dipeptidyl peptidase 4 inhibitors (DPP-4i) vildagliptin 12,13 and sitagliptin, 14 the glucagon-like peptide 1 analogues (GLP-1RAs) liraglutide, 15 the sodium-glucose cotransporter 2 inhibitors (SGLT2i)…”
Self-citationMetabolic consequences of alterations in gut microbiota induced by antidiabetic medications
Chaithanya, V., Kumar, J. S., Leela, K. V., Angelin, M., Satheesan, A., & Murugesan, R. (2023) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2023.100180 · Cited by 6
Tayyib, H. M. U., Ali, A., Jabeen, S., Habib‐ur‐Rehman, Kamran, H., Bajaber, M. A., Usman, M., & Zhang, X. (2024) · BMC Microbiology · doi:10.1186/s12866-024-03218-3 · Cited by 6
“As Clostridium butyricum produced short chain fatty acids and butyrate producing bacteria which improves gut homeostasis and helps in controlling random blood glucose levels especially in diabetes [55].”
BackgroundResultZhen, J., Sun, Y., Zhao, P., Li, C., Wang, H., Li, Y., Zhao, L., Wang, L., Huang, G., & Xu, A. (2021) · BMC Microbiology · doi:10.1186/s12866-021-02221-2 · Cited by 5
“Previous studies have reported that Lachnospira abundance was negatively correlated with fasting blood glucose and the homeostasis model assessment of insulin resistances [19], while a decrease in Lachnospira was presented in individuals with increasing weights during pregnancy and premature delivery caused by preterm…”
ResultMechanisms of Beneficial Effects of Probiotics in Diabetes Mellitus
Sharma, V., Singh, T. G., Dhiman, S., & Garg, N. (2022) · Springer eBooks · doi:10.1007/978-981-16-8444-9_6 · Cited by 6
Bai, Y., Zhang, Y., Wang, Z., Pi, Y., Zhao, J., Wang, S., Han, D., & Wang, J. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.03815-22 · Cited by 5
“Family_X_AD3011_group also had a negative correlation with butyrate; as a conditionally pathogenic bacterium, it could cause gut microbiota dysregulation or excitation states of other pathogenic bacteria, and it is related to depression and metabolic disturbance (54).”
Backgroundde la Bastida, A. R., Langa, S., Peirotén, Á., Curiel, J. A., Fernández‐González, R., Maroto, M., Arqués, J. L., Gutiérrez‐Adán, A., & Landete, J. M. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c06947 · Cited by 4
Zhu, Y., Wu, T., Fu, Y., Zhao, Q., Li, Y., Zhao, L., Zhi, L., Wu, X., Xue, Y., & Shen, Q. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.106187 · Cited by 5
Wen, D., Wang, X. G., He, Y., Hao, X., Huang, W., Zhou, H., Zhang, W., & Li, X. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104379 · Cited by 5
Self-citationMrozińska, S., Gosiewski, T., Sroka-Oleksiak, A., Szopa, M., Bulanda, M., Malecki, M. T., & Klupa, T. (2020) · Clinical Diabetology · doi:10.5603/dk.2019.0024 · Cited by 3
“also observed changes in bacterial flora after administration of vildagliptin in diabetic rats for 12 weeks [14].”
BackgroundAbnormal gut microbiota and impaired incretin effect as a cause of type 2 diabetes mellitus
Demidova, T. Y., Геннадьевна, Л. К., Korotkova, T. N., & Харчилава, Л. Д. (2022) · Medical Herald of the South of Russia · doi:10.21886/2219-8075-2022-13-1-24-42 · Cited by 3
“ZhangQ и соавт.[69] Крысы SpragueDawleyc СД2, возникшим на фоне диеты с избыточным содержанием жиров, n=24 Sprague-Dawleyc rats T2DM on a high-fat diet n = 24 Вилдаглиптин / Vildagliptin 12 недель / 12 weeks ↑: Streptococcus; Bacteroides ↓: Oscillibacter, Ruminiclostridium_6, Anaerotruncus, Eubacterium_ coprostanolige…”
Fan, L., Yang, H. H., Hu, X., Liu, J., You, Y., Li, X., Qin, G., Ge, Q., Hou, Y. X., & Xiao, X. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120515 · Cited by 2
Self-citationQiao, Z., Xing, J., & Li, F. (2023) · Pakistan Journal of Zoology · doi:10.17582/journal.pjz/20230302100304 · Cited by 2
Channo, A., Kaka, A., Memon, A. A., Malhi, M. C., Bakhsh, M., Kalwar, Q., Tunio, S. A., & Panhwar, M. I. (2023) · Pakistan Journal of Zoology · doi:10.17582/journal.pjz/20220523220514 · Cited by 2
Blended Tea Ameliorates T2DM via Modulation of Gut Microflora
Liu, S., Dai, X., Zhao, J., Zhang, X., Zhu, M., Wang, K., & Dong-he, F. (2024) · Plant Foods for Human Nutrition · doi:10.1007/s11130-024-01222-6 · Cited by 2
Lee, H., Son, K., & Kim, J. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2024.106495 · Cited by 4
Aron‐Wisnewsky, J., Lefevre, C., & Bindels, L. B. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2022.01.004 · Cited by 4
Anti‐Diabetic Intestinal Mechanisms: Foods, Herbs, and Western Medicines
Feng, Y., Cao, H., Hua, J., & Zhang, F. (2022) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202200106 · Cited by 2
Cai, M., Ni, Z., Yao, Y., Yu, J. Z., Yu, C., Zhou, L., & Zhai, D. (2022) · Research Square · doi:10.21203/rs.3.rs-1304673/v1 · Cited by 2
The Emerging Role of Gut Microbiota in Metabolic Diseases
Safi, S. Z. (2024) · Premier journal of science. · doi:10.70389/pjs.100020 · Cited by 1
Zhou, P., Liu, Q., Zhao, Y., Wu, Y., Shen, J., Duan, T., Che, L., Zhang, Y., & Yan, H. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1579950 · Cited by 1
Zhu, H., Zuo, S., & Wang, J. (2025) · Hepatitis Monthly · doi:10.5812/hepatmon-163406 · Cited by 1
Olivares, D. V. F., Halverson, T., & Alagiakrishnan, K. (2026) · Future Pharmacology · doi:10.3390/futurepharmacol6020030 · Cited by 2
“Dipeptidyl peptidase 4 (DPP-4) inhibitors are commonly used antidiabetic drugs that have an effect on the microbiome [100].”
Metadata
- Authors
- Zhang, Q., Xiao, X., Li, M., Yu, M., Ping, F., Zheng, J., Wang, T., & Wang, X.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Corresponding author
- Xiao, Xinhua
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-10-16
- Volume
- 12
- Issue
- 10
- Pages
- e0184735
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5643055
- OpenAlex
- W2765808908
- Cited by
- 124
- References
- 56
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 11 · 2023: 26 · 2022: 21 · 2021: 15 · 2020: 14 · 2019: 11 · 2018: 6
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- National Key Research and Development Program of China (2016YFA0101002)
- National Natural Science Foundation of China (81170736, 81570715)
- National Natural Science Foundation for Young Scholars of China (81300649)
- China Scholarship Council Foundation (201308110443)
- PUMC Youth Fund (33320140022)
- China Diabetes Young Scientific Talent Research Funding
- Diabetes Research Fund from Clinical Research of Chinese Medical Association and Chinese Diabetes Society (12030500350)
- Fundamental Research Funds for the Central Universities
- the Scientific Activities Foundation for Selected Returned Overseas Professional of Human Resources and Social Security Ministry
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- vildagliptin, type 2 diabetes, gut microbiota, butyrate-producing bacteria, DPP-4 inhibitors, high-fat diet and streptozotocin-induced diabetes, glucagon-like peptide-1, Firmicutes/Bacteroidetes ratio, Bacteroides, Lachnospira, fasting blood glucose, insulin
- MeSH terms
- Gastrointestinal Microbiome, Vildagliptin, Adamantane, Administration, Oral, Animals, Blood Glucose, Butyrates, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 2, Insulin Resistance, Male, Nitriles, Pyrrolidines, Random Allocation, RNA, Ribosomal, 16S, Interleukin-6, Rats, Sprague-Dawley, Glucagon-Like Peptide 1, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.